Cancer Genetics

Question Title

* 1. Please assess the Sessions overrall

  Strongly Disagree Disagree Neutral Agree Strongly Agree
Sufficient time was allowed for audience participation/active learning
The facilities were satisfactory
The session was free from commercial bias
Overall, I would rate this Symposium as excellent

Please assess each Speaker by their Session:

Question Title

* 2. The Emerging Genetic Basis of Childhood Cancer Susceptibility

Speaker: David Malkin,
Senior Staff Oncologist, Haematolgy/Oncology, Director, Cancer Genetics Program, Professor, Department of Paediatrics, Professor, Department of Medical Biophysics, School of Graduate Studies, Hospital for Sick Children

Objectives: At the end of this session, participants will be able to:
1. Recognize a constellation of cancers and identify the genotype associated with that constellation.
2. Consider the challenges in genetic testing and tumor surveillance in children at risk of cancer.
3. Formulate a strategy to apply emerging technologies (like NGS) to diagnosis of cancer susceptibility syndromes.

  Poor Fair Good Very Good Outstanding
Clarity of Voice
Met Stated Objectives
Balanced & Unbiased
Relevant to Practice Overall
Time for Active Learning

Question Title

* 3. Inherited Susceptibility to Colorectal Polyps and Colorectal Cancer: A Review Focused on New Mendelian Findings

Speaker: William Foulkes,
Professor, Departments of Medicine, Human Genetics and Oncology, McGill University; Director, Program in Cancer Genetics, McGill University

Objectives: At the end of this session, participants will be able to:
1. Describe the new findings in hereditary GI cancers.
2. Distinguish between different syndromes.
3. Examine pedigrees and determine which gene is likely to be responsible.
4. Implement genetic testing for hereditary GI cancers.
5. Recognize the varied manifestations of APC mutations.
6. Critique next generation sequencing as a diagnostic tool.

  Poor Fair Good Very Good Outstanding
Clarity of Voice
Met Stated Objectives
Balanced & Unbiased
Relevant to Practice Overall
Time for Active Learning

Question Title

* 4. Hereditary Pancreatic Cancer

Speaker: Dr. George Zogopoulos,
Assistant Professor, Surgery, McGill University, Surgeon, McGill University Centre, Cancer Research Society, Montréal QC Canada

Objectives: At the end of this session, participants will be able to:
1. Describe the incidence and current treatment landscape of pancreatic cancer.
2. Describe causes of hereditary pancreatic cancer.
3. Provide an overview of emerging therapies for pancreatic cancer subtypes.
4. Discuss genetic testing for pancreatic cancer.
5. Consider the evidence for clinical screening of individuals at increased risk for pancreatic cancer.

  Poor Fair Good Very Good Outstanding
Clarity of Voice
Met Stated Objectives
Balanced & Unbiased
Relevant to Practice Overall
Time for Active Learning

Question Title

* 5. Breast and Ovarian Cancer Genetics: An Update for 2016

Speaker: Dr. William Foulkes,
Professor, Departments of Medicine, Human Genetics and Oncology, McGill University, Director, Program in Cancer Genetics, McGill University, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montréal QC Canada

  Poor Fair Good Very Good Outstanding
Clarity of Voice
Met Stated Objectives
Balanced & Unbiased
Relevant to Practice Overall
Time for Active Learning

Question Title

* 6. Dissecting the Clinical Genomics of Therapy-Resistant Prostate Cancer Through Liquid Biopsy

Speaker: Dr. Alexander Wyatt,
Senior Research Scientist, Vancouver Prostate Centre, Assistant Professor, Department of Urologic Sciences, University of British Columbia, Gordon and Leslie Diamond Health Care Centre, Vancouver General Hospital, Vancouver BC Canada

Objectives: At the end of this session, participants will be able to:
1. Describe the landscape of germline and somatic alterations that contribute to castration-resistant prostate cancer
2. List genomic alterations detectable in patient liquid biopsies that are associated with resistance to Androgen Receptor (AR) targeted therapy
3. Discuss the potential for circulating cell-free tumor DNA (ctDNA) to be a biomarker for predicting patient response to AR-targeted therapy
4. Summarize the spectrum of clinically-informative changes that are detectable in patient ctDNA and how these alterations can aid clinical trial enrichment

  Poor Fair Good Very Good Outstanding
Clarity of Voice
Met Stated Objectives
Balanced & Unbiased
Relevant to Practice Overall
Time for Active Learning

Question Title

* 7. As a result of attending this session, I am planning to:

Question Title

* 8. Please explain any changes you plan to make or personal learning projects you will pursue as a result of this session:

Question Title

* 9. Please indicate which CanMEDS roles you felt were addressed during this educational activity. (Select all that apply)

Question Title

* 10. General comments about individual speaker:

Question Title

* 11. What topics would you like to be addressed at future conferences to keep you up to date in your profession?

T